Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05540717
Other study ID # PQGrass306
Secondary ID 2019-001517-16
Status Completed
Phase Phase 3
First received
Last updated
Start date October 11, 2022
Est. completion date November 1, 2023

Study information

Verified date January 2024
Source Allergy Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PQGrass306 (G306) clinical trial is the pivotal Phase III efficacy clinical trial of PQ Grass. The aim of the G306 pivotal clinical trial is to confirm the efficacy and safety of the optimal effective dose of PQ Grass 27600 SU. This will be determined through the measurements of the effect of PQ Grass on the symptoms of seasonal allergic rhinitis (SAR)/rhinoconjunctivitis and the use of relief medications to control these symptoms during the peak grass pollen season (GPS).


Description:

Multi-centre, randomised, parallel group, double-blind, placebo-controlled clinical trial to confirm the efficacy and safety of the optimal effective dose of PQ Grass (27600 SU). Randomized study subjects, in a randomisation ratio of 1:1, will receive either treatment with 6 injections of active treatment (900, 2700, 6000, 6000, 6000 and 6000 SU sequentially) to achieve a cumulative nominal dose of 27600 SU, or 6 injections of placebo prior to the onset of the grass pollen season (GPS). The aim of the study is to confirm the efficacy and safety of the optimal effective dose of the PQ Grass 27600 SU dose. Efficacy will be determined through the measurements of the effect of PQ Grass on the symptoms of seasonal allergic rhinitis (SAR)/rhinoconjunctivitis and the use of relief medications to control these symptoms during the peak GPS.


Recruitment information / eligibility

Status Completed
Enrollment 858
Est. completion date November 1, 2023
Est. primary completion date November 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the ICF (informed consent form) and in this clinical trial protocol and to attend required clinical trial visits. 2. Subject who has a signed and dated ICF. 3. Subject must be 18 to 65 years of age inclusive, at the time of signing the ICF. 4. Male or female. 5. Female subjects who are not of childbearing potential (defined as at least 12 months natural spontaneous amenorrhoea, or at least 6 weeks following surgical menopause/permanent sterilisation [hysterectomy, bilateral oophorectomy and bilateral salpingectomy]) or females of childbearing potential who agree to comply with the contraceptive requirements of the clinical trial protocol. 6. Good general health, as determined by the Investigator, based on a medical evaluation, including medical history, physical examination, mental status assessment and laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the clinical trial procedures. 7. Positive history of moderate to severe symptoms of SAR/rhinoconjunctivitis ascribed to grass (Pooideae) pollen exposure of at least 2 seasons duration, despite having received allergy pharmacotherapy (e.g., antihistamines, nasal corticosteroids, leukotriene modifiers, etc.) during the last 2 consecutive grass pollen seasons prior to the clinical trial, confirmed by subject records. Please note: Subjects with asthma may be included, but the asthma must be well controlled (according to current Global Initiative for Asthma [GINA] guidelines [GINA 2022]). 8. A positive SPT (skin prick test) to histamine (wheals [longest diameter] =3 mm) and a negative SPT to the negative control (wheal diameter = 0 mm) at screening. 9. A positive SPT for grass pollen (wheals [longest diameter] =3 mm). 10. Grass specific IgE (immunoglobulin E) class =2 as documented by an ImmunoCAP test at screening. 11. Forced expiratory volume in one second (FEV1) =70% of predicted, with a FEV1/forced vital capacity (FVC) ratio >75% and PEFR (peak expiratory flow rate) =70% of predicted at screening. Exclusion Criteria: 1. Pregnant or lactating subject. 2. Presence of any medical history of moderate to severe allergy symptoms (verified by a positive SPT at screening or positive specific IgE [=2] at screening) to any other seasonal allergen (other than grass) or perennial allergens. Exception: Period 1, Period 2 and Period 3 of the entire clinical trial will be conducted outside of the pollen season(s) of concern or perennial allergies are irrelevant due to avoidance measures (e.g., cats and dog allergy). Subjects with mild allergy symptoms (only) to any other allergen apart from grass may be included at the discretion of the Investigator. In countries in Europe where Bermuda grass is present, any medical history of moderate to severe allergy symptoms to Bermuda grass (verified by a positive SPT or positive specific IgE [Class =2]), will also represent a reason for exclusion as it will not be possible to conduct Period 1, Period 2 and Period 3 of the entire clinical trial outside of Bermuda grass pollen season. Albeit Bermuda grass being commonly defined as a grass, it belongs to the Poaceae family, while the sentence (other than grass) in Exclusion criterion #2 refers to grass of Pooideae subfamily (as defined in Inclusion criterion #7). 3. Subjects at US clinical trial sites in regions where southern grasses (Bahia grass, Bermuda grass or Johnson grass) are the dominant grasses and the main cause of grass allergy symptoms with a positive SPT to any of the 3 grasses (irrespective of the severity of symptoms). 4. Moderate to severe symptoms during the 3 years prior to Visit 1 to any other seasonal or perennial allergen not tested in the SPT done at screening that cannot be avoided during the Period 1 to Period 3 of the clinical trial and the symptoms of which may interfere with administration of treatment and/or impact the data collected. 5. Presence of any medical condition that may reduce the ability to survive a serious allergic reaction. 6. Presence of active systemic autoimmune disorder, systemic autoimmune disorders in remission or active organ specific autoimmune disorder. 7. Presence of active malignant neoplasia, severe cardiovascular disease (e.g., coronary artery disease, cardiac insufficiency, etc.), pulmonary insufficiency, severe psychiatric disorders or primary and secondary immunodeficiencies. 8. History of any other immunological disorder or other diseases (including, but not limited cardiovascular [including uncontrolled or inadequately controlled hypertension], gastro-intestinal, hepatic, renal, haematological, neurological, endocrine or pulmonary disease) that in the opinion of the Investigator may pose a safety risk or compromise the interpretation of efficacy of the clinical trial treatment. 9. Presence of severe or poorly controlled or uncontrolled asthma as defined by at least 1 of the following criteria: 1. Severe asthma (as per the current GINA guidelines [GINA, 2022]). 2. Uncontrolled or poorly controlled asthma as per the current GINA guidelines (GINA, 2022). 3. Asthma that requires more than a daily dose above 800 µg of inhaled budesonide (or clinically comparable inhaled corticosteroid) as per the current GINA guidelines (GINA, 2022). 4. History of 2 or more systemic corticosteroid courses within 6 months of screening or Visit 2 or 1 course of systemic corticosteroids within 3 months of screening or Visit 2 to treat asthma. 5. Prior intubation/mechanical ventilation for asthma. 6. Emergency room visit or hospitalisation for asthma in the 12 months prior to screening or Visit 2. 7. Any history of a life-threatening asthma attack. 8. FEV1 <70% of predicted or FEV1/FVC =75% or PEFR <70% of predicted with or without controller medications at screening or Visit 2. 10. Presence non-atopic rhinitis and/or rhino-sinusitis (with or without polyps). 11. Presence of nasal polyps and/or chronic sinusitis. 12. Presence of any acute or chronic ocular disorder, other than allergic conjunctivitis. 13. Eye surgery within the past 6 months. 14. Presence of any skin conditions (e.g., skin abnormalities, tattoos etc.), which might interfere with the interpretation of the SPT results. 15. Clinical history of Type I diabetes or poorly controlled Type II diabetes. 16. Moderate to severe upper or lower respiratory infections requiring medication within 14 days before screening (Visit 1) or Visit 2. 17. Presence of acute or chronic infection, fever or inflammation at screening or Visit 2. 18. Clinical history of severe systemic reaction or serious systemic reaction in response to AIT (allergen immunotherapy) in the past. 19. Clinical history of severe or life-threatening anaphylactic reactions to foods, insect venom, exercise, drugs or idiopathic anaphylaxis. 20. Clinical history of allergy, hypersensitivity or intolerance to the excipients of the investigational drug/placebo. 21. Clinical history of allergy, hypersensitivity or intolerance to the relief medications (for relief of allergy symptoms during Period 3) provided for use in this clinical trial. 22. Clinical history of hereditary angioedema. 23. Unable to receive epinephrine therapy (i.e., use of epinephrine is contraindicated such as in subjects with hyperthyroidism, uncontrolled hypertension, cardiac arrhythmias, closed angle glaucoma or subjects taking other sympathomimetics). 24. Tyrosine metabolism disorders, especially tyrosinemia and alkaptonuria. 25. Clinical history of drug or alcohol abuse, which, in the Investigator's opinion, could interfere with the subject's ability to participate in the clinical trial. 26. Subjects who have suspicion or symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (as assessed by the Investigator) or who have had unprotected contact with a confirmed case of COVID-19 (coronavirus disease 2019) in the 2 weeks prior to screening or Visit 2 (based on the Investigator's discretion). 27. Subjects who were hospitalised for COVID-19 within 6 months prior to screening or Visit 2. 28. Any history of AIT for grass pollen allergy in the past or history of AIT for any other type of allergy (excluding food allergy) in the past 5 years. 29. Inability to adhere to the washout periods listed in the protocol, with respect to screening and to refrain from using the medications indicated until after Visit 11. 30. Treatment with a preparation containing MPL (monophosphoryl lipid-A) (e.g., Cervarix, Shingrix, Fendrix) within 2 years prior to Visit 1 and until after completion of Visit 11 (with the exception of the investigational drug). 31. Previous history of epinephrine auto-injector use. 32. ß-blocker medication (local or systemic, including eye drops) for any indication. 33. Monoamine oxidase inhibitors and tricyclic antidepressants. Please note: Tricyclic antidepressants should be avoided at least 2 weeks prior to screening. 34. Any previous therapy (within the previous 5 years) or current therapy with anti IgE (e.g., omalizumab [Xolair]) or anti-interleukins (e.g., mepolizumab). 35. Current or past therapy (within the previous 5 years) with any other immunomodulatory biologics. 36. Unable to refrain from any vaccination (including influenza vaccine and COVID-19 vaccine) during the clinical trial (unless administered >30 days prior to randomisation). Please note: Emergency vaccinations (e.g., tetanus due to injury) can be administered at any time. Booster vaccinations (only) for COVID-19 can be administered during the clinical trial apart from during the treatment period. There should be at least 14 days interval from the last administration of the investigational drug/placebo prior to administration of a COVID-19 booster injection. 37. Participation in a clinical research trial with any investigational drug within 4 weeks of Visit 1 or concomitantly with this clinical trial. Please note: The period of exclusion begins at the time of the last visit of the prior clinical research trial. Subjects consented and screened, but not dosed in the prior clinical research trial are not excluded. 38. Personal, financial or other dependent relationship (e.g., employee or immediate relative) with the clinical trial site, Sponsor, Sponsor's representative, or another individual who has access to the clinical trial protocol. 39. Vulnerable subjects or those in judicial or governmental detention, detainment or imprisonment in a public institution. 40. Subjects likely to have prolonged periods of absence (e.g., business or personal travel) during the GPS defined as: - Absence of a total of 22 days or more in similar geographical regions (as determined by the Investigator), with no single trip in a similar geographical region exceeding 14 days. - Absence of a total of 15 days or more in non-similar geographic regions (as determined by the Investigator), with no single trip in a non-similar geographical region exceeding 7 days. 41. Have changed residence to a different geographical region(s) since the last GPS. Exception: The old and new residences are in the same or similar geographical region as determined by the Investigator.

Study Design


Intervention

Biological:
PQ Grass
Suspension for Injection
Placebo
Solution for injection

Locations

Country Name City State
Austria Medizinische Universitaet Innsbruck - Universitatsklinik fuer Dermatologie, Venerologie und Allergologie Innsbruck
Austria Bezirkskrankenhaus Kufstein Kufstein
Austria Ambulatorium für Allergie und klinische Immunologie AAKI Wien
Austria Medizinische Universitat Wien (Medical University of Vienna) Wien
Czechia Fakultní nemocnice u sv. Anny v Brne Brno
Czechia MUDr. Jana Poloniová - alergologie a klinická imunologie Ceské Budejovice
Czechia Alergopraktik, s.r.o. Jablonec Nad Nisou
Czechia Alergologie a imunologie MUDr. Hofstetr Jihlava
Czechia Alergoimuno s.r.o. Ostrava-Hrabuvka
Czechia ACREDULA BENEDICTA s.r.o. Pardubice
Czechia Fakultní nemocnice Plzen Plzen
Czechia KASMED, s.r.o. Tábor
Czechia MUJ ALERGOLOG s.r.o. Trutnov
Germany CIMS Studienzentrum Bamberg, GmbH Bamberg
Germany Charité - Universitaetsmedizin Berlin Klinik fuer Dermatologie, Venerologie und Allergologie/ Abteilung Allergologie und Immunologie Berlin
Germany Praxis Dr. Petra El-Naib Chemnitz
Germany HNO-Praxis Dr. Udo Schaefer Dresden
Germany Klinische Forschung Dresden GmbH Dresden
Germany Praxis fuer HNO und Allergologie Dresden
Germany Universitaetsklinikum Carl Gustav Carus an der TU Dresden Dresden
Germany RKM740 Hals-Nasen-Ohrenheilkunde Duesseldorf
Germany HNO-Praxis Dr. Uta Thieme Duisburg
Germany Gemeinschaftspraxis Ruhr Essen
Germany Medizentrum Essen Borbeck Essen
Germany Medaimun GmbH Frankfurt am Main
Germany medicoKIT GmbH Goch
Germany Hamburger Institut für Therapieforschung GmbH Hamburg
Germany Klinische Forschung Hamburg GmbH Hamburg
Germany Velocity Clinical Research Hamburg Hamburg
Germany Praxis Dres. med. Florian Heimlich und Angelika Witzel-Heimlich Heidelberg
Germany HNO-Praxis Landsberg Landsberg
Germany Praxis fuer Pneumologie und Allergologie Leipzig
Germany Sektion Rhinologie/Allergologie Klinik fuer HNO-Heilkunde, UKGM - Marburg Marburg
Germany Beldio Research GmbH Memmingen
Germany Facharztpraxis Dr. med. Jan-Christof Bohn Mittweida
Germany Ballenberger, Freytag, Wenisch Institut fuer klinische Forschung GmbH Neu Isenburg
Germany Studienzentrum Maerkisch-Oderland Neuenhagen
Germany KliFOs - Klinische Forschung Osnabrueck Osnabrück
Germany Studienzentrum Dr. Sabine Lassmann Saalfeld
Germany Klinische Forschung Schwerin GmbH Schwerin
Germany Klinikum Stuttgart - Krankenhaus Bad Cannstatt (KBC) - Frauenklinik Stuttgart
Germany Dres. med. Josef und Wilma Grosskopf Wallerfing
Hungary Gróf Tisza István Kórház Rendelointézet MEDIDOCUMENT Kereskedelmi és Szolgáltató Betéti Társaság Berettyóújfalu
Hungary Clinexpert Kft Budapest
Hungary HiTech Medical Kft. Budapest
Hungary Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar Pécs
Poland Allergy Clinic Homeo Medicus Bialystok
Poland Prywatny Gabinet Internistyczno - Alergologiczny Bialystok
Poland Centrum Medyczne Czestochowa - PRATIA - PPDS Czestochowa
Poland Centrum Medyczne Pratia Katowice Katowice
Poland Specjalistyczna Praktyka Lekarska dr n. med. Joanna Orlicz-Widawska Katowice
Poland ETG Kielce Kielce
Poland Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o. Kraków
Poland Krakowskie Centrum Medyczne Kraków
Poland Malopolskie Centrum Alergologii Kraków
Poland ETG Lódz Lódz
Poland Uniwersytecki Szpital Kliniczny im. Barlickiego, Poradnia alergologii i chorob pluc Lódz
Poland Clinical Best Solutions Sp. Z O.O. Spólka Komandytowa Lublin
Poland Centrum Alergologii Teresa Hofman Sp. z o.o. Poznan
Poland Specjalistyczna Przychodnia Lekarska ALERGO-MED Sp. z.o.o. Poznan
Poland EMED Centrum Uslug Medycznych Ewa Smialek Rzeszów
Poland ETG Skierniewice Skierniewice
Poland ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z.o.o Tarnów
Poland Specjalistyczne Centrum Medyczne Centermed Sp. z o.o. Tarnów
Poland IRMED Irena Wojciechowska Warszawa
Poland WK Medical Service Sp. z o.o. Warszawa
Poland "ALL-MED" Specjalistyczna Opieka Medyczna, Medyczny Instytut Badawczy Wroclaw
Poland Michal Bogacki - DOBROSTAN Wroclaw
Poland Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Lekarska Hipokrates Sp. z o.o. Zabrze
United States Northern Light Allergy and Immunology Bangor Maine
United States Paul A. Shapero M.D. Bangor Maine
United States Nebraska Medical Research Institute, The Asthma & Allergy Center Bellevue Nebraska
United States Bellingham Asthma Allergy and Immunology Clinic Bellingham Washington
United States Allergy & Asthma Specialists Blue Bell Pennsylvania
United States IMMUNOe Research Centers Centennial Colorado
United States Allergy Asthma and Immunology Research Institute Charlotte North Carolina
United States Bernstein Clinical Research Center, LLC Cincinnati Ohio
United States Cincinnati Allergy and Asthma Center Cincinnati Ohio
United States Clinical Research of The Ozarks Inc - Warrensburg Columbia Missouri
United States Optimed Research Ltd Columbus Ohio
United States Velocity Clinical Research Denver Denver Colorado
United States Lysosomal Rare Disorders Research & Treatment Center Fairfax Virginia
United States Velocity Clinical Research, Inc Grants Pass Oregon
United States Allergy, Asthma & Sinus Center, S.C. Greenfield Wisconsin
United States Parikh Institute for Research LLC Highland Park New Jersey
United States Allergy and Asthma Associates of Bluegrass Lexington Kentucky
United States Allergy Partners of Central Kentucky Lexington Kentucky
United States Family Allergy Asthma Research Institute Louisville Kentucky
United States University of Wisconsin Clinical Science Center Madison Wisconsin
United States Velocity Clinical Research - Medford - ERN - PPDS Medford Oregon
United States Montana Medical Research Missoula Montana
United States Allergy Associate of Utah Murray Utah
United States Eastern Virginia Medical School Norfolk Virginia
United States Atlantic Research Center LLC Ocean City New Jersey
United States Oklahoma Institute of Allergy and Asthma Clinical Research, LLC - CRN - PPDS Oklahoma City Oklahoma
United States Allergy & Asthma Specialists PSC Owensboro Kentucky
United States Allergy and Clinical Immunology Associates Pittsburgh Pennsylvania
United States Northwest Research Center Portland Oregon
United States Weiss Medical Riverdale New Jersey
United States Toledo Institute of Clinical Research Inc Toledo Ohio
United States Chesapeake Clinical Research Inc White Marsh Maryland
United States Respiratory Medicine Research Institute of Michigan Ypsilanti Michigan

Sponsors (1)

Lead Sponsor Collaborator
Allergy Therapeutics

Countries where clinical trial is conducted

United States,  Austria,  Czechia,  Germany,  Hungary,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Combined symptom and medication score (CSMS) averaged over the peak grass pollen season (GPS) 6 individual symptoms assessed in a 4 point severity scale (0-No symptoms to 3-Severe symptoms) and combined with relief medication use assessed using a 4 point severity scale (0=No relief medication, 1=anti-histamine use, 2=nasal corticosteroid use, and 3=oral corticosteroid use). Approximately 2-5 weeks
Secondary Serum grass specific IgG4 (immunoglobulin G4) at Visit 7 compared to baseline. Approximately 16-22 weeks
Secondary The number of well days during the peak GPS. Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS
Secondary Rhinoconjunctivitis Quality of Life Questionnaire with standardised activities (RQLQ(S)) measured within the peak GPS Rhinoconjunctivitis quality of life questionnaire with standardised activities - RQLQ(S).
7-point scale (0 = not impaired at all - 6 = severely impaired). Scoring available: higher scores reflect lower quality of life.
Up to approximately 6 months
Secondary Frequency, severity and relationship of AEs (adverse event) to treatment Up to 1 year
Secondary Frequency of AEs leading to premature discontinuation from treatment or clinical trial Up to 1 year
Secondary Frequency of AESI (adverse events of special interest) Up to 1 year
Secondary Changes in serum chemistry values between screening and Visit 11 Including sodium, potassium and chloride concentration (mmol/L) 8 months approximately
Secondary Changes in serum chemistry values between screening and Visit 11 Including glucose, uric acid, urea, phosphorus and cholesterol concentration (mmol/L) 8 months approximately
Secondary Changes in serum chemistry values between screening and Visit 11 Including calcium, creatinine and total bilirubin concentration (µmol/L) 8 months approximately
Secondary Changes in serum chemistry values between screening and Visit 11 Including total protein and albumin concentration (g/L) 8 months approximately
Secondary Changes in serum chemistry values between screening and Visit 11 Including alkaline phosphatase, LDH (lactate dehydrogenase), AST (aspartate aminotransferase), ALT (alanine aminotransferase) and GGT (gamma-glutamyl transferase) (U/L) 8 months approximately
Secondary Changes in serum chemistry values between screening and Visit 11 Including CRP (C-reactive protein) (mg/L) 8 months approximately
Secondary Changes in haematology values between screening and Visit 11 Including total RBC (red blood cells) and differential (10^12/L) 8 months approximately
Secondary Changes in haematology values between screening and Visit 11 Including total WBC (white blood cells) and differential and platelet count (10^9/L) 8 months approximately
Secondary Changes in haematology values between screening and Visit 11 - Haemoglobin Haemoglobin concentration 8 months approximately
Secondary Changes in clinical laboratory values (urinalysis) between screening and Visit 11 Urinalysis (using a urine dip-stick) pH - Results will be assessed by the investigators as clinical significant or not 8 months approximately
Secondary Changes in clinical laboratory values (urinalysis) between screening and Visit 11 Urinalysis (using a urine dip-stick) protein, glucose, bilirubin, blood and leukocytes - Results will show zero, traces, +1, +2, +3, +4 Note: Microscopic examination will be conducted if protein, leukocytes and/or blood are detected. If needed, microscopic examination will include WBC, RBC, casts, and bacteria. 8 months approximately
Secondary Changes in clinical laboratory values (urinalysis) between screening and Visit 11 Urinalysis (using a urine dip-stick) Ketones, nitrite, urobilinogen - Results will show negative or positive Note: Microscopic examination will be conducted if nitrite are detected. If needed, microscopic examination will include WBC, RBC, casts, and bacteria. 8 months approximately
Secondary Changes in vital signs at all treatment visits Systolic and diastolic blood pressure 7 months approximately
Secondary Combined symptom and medication score (CSMS) averaged over the entire (or truncated) grass pollen season (GPS) 6 individual symptoms assessed in a 4 point severity scale (0-No symptoms to 3-Severe symptoms) and combined with relief medication use assessed using a 4 point severity scale (0=No relief medication, 1=anti-histamine use, 2=nasal corticosteroid use, and 3=oral corticosteroid use) Time Frame: Approximately 10 weeks
Secondary Daily symptom score (dSS) component of the CSMS averaged over the peak GPS and entire (or truncated) GPS Sum of the scores (0-No symptoms to 3-Severe symptoms) for the 6 individual symptoms assessed in CSMS divided by 6 Time Frame: Time Frame: Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS
Secondary Daily medication score (dMS) component of the CSMS averaged over the peak GPS and entire (or truncated) GPS Score 0 (no relief medication) to 3 (highest step relief medication) per day; based on at least 1 dose of the medication of the highest step taken that day Time Frame: Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS
See also
  Status Clinical Trial Phase
Terminated NCT01337323 - Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting N/A
Completed NCT01171664 - Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects Phase 2
Completed NCT00784732 - A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber Phase 2
Completed NCT00619827 - Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract Phase 1
Completed NCT00578929 - Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients Phase 3
Completed NCT00209365 - The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit N/A
Terminated NCT00223587 - Seasonal Allergic Rhinitis and Driving Ability Phase 4
Completed NCT00637455 - Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel Phase 4
Completed NCT00963599 - Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117) Phase 3
Recruiting NCT05346718 - Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis N/A
Completed NCT06126952 - Azelastine Allergen Chamber - Onset of Action Study Phase 2
Completed NCT02245360 - Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis Phase 3
Completed NCT01940146 - Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis Phase 2
Completed NCT01230619 - Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis Phase 2
Completed NCT00561717 - A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis Phase 4
Completed NCT00574210 - PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm) Phase 2
Completed NCT00443495 - Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis Phase 1/Phase 2
Completed NCT00405899 - Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections N/A
Completed NCT00420082 - A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber Phase 2
Completed NCT03097432 - Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment N/A